Jericho Sciences is developing a novel lead antiviral therapeutic small molecule demonstrating unique long term activities to specifically address the limitations of current combination antiretroviral therapy (cART) in the clinical management of HIV-1 infection. Our goal is to support long term remission for people living with HIV.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
North Carolina
Company HQ Country:
United States
Year Founded:
2009
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
Small Molecule with long term activities
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
